Century Therapeutics, Inc.

IPSCNASDAQHealthcare● Active

$2.12

$-0.01(-0.47%)

Market Cap$183527105

P/E Ratio—

52W High$3.04

52W Low$0.435

Avg Volume1.2M

Open$2.13

Beta1.57

Overview

Century Therapeutics, Inc. (IPSC) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

IPSC · free cash flow · updated Jun 9, 2026

Core FCF metrics

IPSC · FCF · TTM · margin & CAGR

Free cash flow was −$104.7M for FY2025 (fiscal year ending 2025-12-31), up 5.0% year-over-year The FCF margin was -95.9%.

FY2025 Free Cash Flow−$104.7M▲ +5.0% YoY

Trailing 12M (TTM)−$95.9Mtrailing 4 quarters sum

FCF Margin-95.9%−$104.7M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

IPSC · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$103.9M(1M)−$104.7M▲ +5.0%-95.9%

FY2024−$110.1M(0M)−$110.3M▼ 8.0%—

FY2023−$88.3M(14M)−$102.1M▼ 516.7%—

FY2022$14.1M(31M)−$16.6M▲ +87.6%-318.4%

FY2021−$89.0M(45M)−$134.0M▼ 162.2%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

IPSC · P/FCF · FCF yield · FCF per share

Century Therapeutics, Inc. (IPSC) reported negative free cash flow of −$0.10B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

IPSC · cash flow statement · operating / investing / financing

For FY2025, Century Therapeutics, Inc. generated −$103.9M in operating cash flow and spent 1M in capital expenditures, yielding −$104.7M in free cash flow.

Operating Activities

−$103.9M

Cash from core business operations

2025-12-31

Investing Activities

+$107.5M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$0.2M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$103.9M) − |CapEx| (1M) = FCF (−$104.7M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

IPSC vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Century Therapeutics, Inc.YOU

IPSC

−$104.7M+5.0%-95.9%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Century Therapeutics, Inc. (IPSC) reported free cash flow of −$104.7M for FY2025 (fiscal year ending 2025-12-31), up 5.0% year-over-year. The FCF margin was -95.9%.

Century Therapeutics, Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 7 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

IPSC free cash flow · 8 questions

Century Therapeutics, Inc. free cash flow was −$104.7M for FY2025, up 5.0% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$95.9M.

IPSC free cash flowIPSC FCFIPSC FCF 2025IPSC free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Century Therapeutics, Inc. · Century Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026